303 related articles for article (PubMed ID: 35584326)
41. Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice.
Floer M; Götte M; Wild MK; Heidemann J; Gassar ES; Domschke W; Kiesel L; Luegering A; Kucharzik T
Am J Pathol; 2010 Jan; 176(1):146-57. PubMed ID: 20008145
[TBL] [Abstract][Full Text] [Related]
42. Syndecan-1 (CD138) as a Pathogenesis Factor and Therapeutic Target in Breast Cancer.
Sheta M; Götte M
Curr Med Chem; 2021; 28(25):5066-5083. PubMed ID: 34191695
[TBL] [Abstract][Full Text] [Related]
43. Expression of syndecan-1 in oral cavity squamous cell carcinoma.
Woźniak M; Nahajowski M; Hnitecka S; Rutkowska M; Nowak M; Mitelsztet P; Szkudlarek D; Makuch S
J Histotechnol; 2021 Mar; 44(1):46-51. PubMed ID: 33357145
[TBL] [Abstract][Full Text] [Related]
44. Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases.
Kim SY; Choi EJ; Yun JA; Jung ES; Oh ST; Kim JG; Kang WK; Lee SH
Int J Med Sci; 2015; 12(2):92-9. PubMed ID: 25589885
[TBL] [Abstract][Full Text] [Related]
45. Association of heparan sulfate proteoglycans SDC1 and SDC4 polymorphisms with breast cancer in an Australian Caucasian population.
Okolicsanyi RK; Buffiere A; Jacinto JM; Chacon-Cortes D; Chambers SK; Youl PH; Haupt LM; Griffiths LR
Tumour Biol; 2015 Mar; 36(3):1731-8. PubMed ID: 25361632
[TBL] [Abstract][Full Text] [Related]
46. Syndecan-1 (CD138), Carcinomas and EMT.
Couchman JR
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921767
[TBL] [Abstract][Full Text] [Related]
47. Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation.
Beauvais DM; Rapraeger AC
J Cell Sci; 2010 Nov; 123(Pt 21):3796-807. PubMed ID: 20971705
[TBL] [Abstract][Full Text] [Related]
48. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.
Ramani VC; Purushothaman A; Stewart MD; Thompson CA; Vlodavsky I; Au JL; Sanderson RD
FEBS J; 2013 May; 280(10):2294-306. PubMed ID: 23374281
[TBL] [Abstract][Full Text] [Related]
49. Relationship between SDC1 and cadherin signalling activation in cancer.
Liao S; Liu C; Zhu G; Wang K; Yang Y; Wang C
Pathol Res Pract; 2020 Jan; 216(1):152756. PubMed ID: 31810587
[TBL] [Abstract][Full Text] [Related]
50. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis.
Qiao W; Liu H; Guo W; Li P; Deng M
Eur J Surg Oncol; 2019 Jul; 45(7):1132-1137. PubMed ID: 30598194
[TBL] [Abstract][Full Text] [Related]
51. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.
Szarvas T; Sevcenco S; Módos O; Keresztes D; Nyirády P; Kubik A; Romics M; Kovalszky I; Reis H; Hadaschik B; Shariat SF; Kramer G
Urol Oncol; 2018 Jun; 36(6):312.e9-312.e15. PubMed ID: 29628317
[TBL] [Abstract][Full Text] [Related]
52. Low Soluble Syndecan-1 Precedes Preeclampsia.
Gandley RE; Althouse A; Jeyabalan A; Bregand-White JM; McGonigal S; Myerski AC; Gallaher M; Powers RW; Hubel CA
PLoS One; 2016; 11(6):e0157608. PubMed ID: 27299886
[TBL] [Abstract][Full Text] [Related]
53. Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility.
Yang N; Mosher R; Seo S; Beebe D; Friedl A
Am J Pathol; 2011 Jan; 178(1):325-35. PubMed ID: 21224069
[TBL] [Abstract][Full Text] [Related]
54. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
55. Impaired arteriogenesis in syndecan-1(-/-) mice.
Tang GL; Weitz K
J Surg Res; 2015 Jan; 193(1):22-7. PubMed ID: 25194470
[TBL] [Abstract][Full Text] [Related]
56. Targeting of heparanase-modified syndecan-1 by prosecretory mitogen lacritin requires conserved core GAGAL plus heparan and chondroitin sulfate as a novel hybrid binding site that enhances selectivity.
Zhang Y; Wang N; Raab RW; McKown RL; Irwin JA; Kwon I; van Kuppevelt TH; Laurie GW
J Biol Chem; 2013 Apr; 288(17):12090-101. PubMed ID: 23504321
[TBL] [Abstract][Full Text] [Related]
57. Targeting of syndecan-1 by micro-ribonucleic acid miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic milieu and interleukin-6 secretion.
Schneider C; Kässens N; Greve B; Hassan H; Schüring AN; Starzinski-Powitz A; Kiesel L; Seidler DG; Götte M
Fertil Steril; 2013 Mar; 99(3):871-881.e1. PubMed ID: 23206733
[TBL] [Abstract][Full Text] [Related]
58. Syndecan-1 Mediates Sorting of Soluble Lipoprotein Lipase with Sphingomyelin-Rich Membrane in the Golgi Apparatus.
Sundberg EL; Deng Y; Burd CG
Dev Cell; 2019 Nov; 51(3):387-398.e4. PubMed ID: 31543446
[TBL] [Abstract][Full Text] [Related]
59. MiR-302a inhibits the tumorigenicity of ovarian cancer cells by suppression of SDC1.
Guo T; Yu W; Lv S; Zhang C; Tian Y
Int J Clin Exp Pathol; 2015; 8(5):4869-80. PubMed ID: 26191180
[TBL] [Abstract][Full Text] [Related]
60. Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication.
Szatmári T; Ötvös R; Hjerpe A; Dobra K
Dis Markers; 2015; 2015():796052. PubMed ID: 26420915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
